[Extra-membranous glomerulonephritis: from the experimental model to the human pathology of new-born and adult].
Membranous nephropathy (MN) is one of the most common glomerulopathies. Current treatments are entirely empirical, and concept-driven therapies are dramatically lacking. In the rat experimental model established by Heymann in 1959, the target antigen is expressed at the surface of podocytes where immune complexes are formed, inducing complement activation results in heavy proteinuria. However, megalin is not detected on human podocytes and in immune deposits in patients with MN. We recently identified neutral endopeptidase (NEP), a podocyte antigen that can digest biologically active peptides, as the target antigen of antibodies deposited in the subepithelial space of glomeruli in a subset of patients with antenatal MN. The mothers became immunized because they are deficient in NEP due to truncating mutations in the gene. MN could be transferred to the rabbit by injection of mothers' Ig. We discuss new pathophysiological aspects of the disease with special emphasis on allo-immunization, novel potential antigenic targets, and therapeutic prospects.
Ronco
P
P
Unité Inserm UMR S702 et Département de Néphrologie, Hôpital Tenon, Paris, France.
D000328:Adult; D000818:Animals; D015433:Glomerulonephritis, Membranous / Q000276:immunology* / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy; D006801:Humans; D007231:Infant, Newborn; D026561:Low Density Lipoprotein Receptor-Related Protein-2 / Q000276:immunology; D015260:Neprilysin / Q000276:immunology; D050199:Podocytes / Q000276:immunology; D011817:Rabbits; D051381:Rats
D026561:Low Density Lipoprotein Receptor-Related Protein-2; D015260:Neprilysin